Lyra Therapeutics (LYRA) Institutional Ownership $7.41 +0.41 (+5.86%) Closing price 04:00 PM EasternExtended Trading$7.17 -0.24 (-3.29%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Lyra Therapeutics (NASDAQ:LYRA)CurrentInstitutional OwnershipPercentage95.62%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$14.31MNumber ofInstitutional Sellers(last 12 months)6TotalInstitutional Outflows(last 12 months)$133.29M Get LYRA Insider Trade Alerts Want to know when executives and insiders are buying or selling Lyra Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Chart & View Institutional Buying and Selling Data LYRA Institutional Buying and Selling by Quarter Lyra Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails8/15/2025 Perceptive Advisors LLC255,150$2.29M0.2%-98.0%15.558% 8/15/2025 Bank of America Corp DE28,542$256K0.0%+33.7%1.740% 8/8/2025 Geode Capital Management LLC10,986$98K0.0%-98.9%0.687% 6/27/2025 Goldman Sachs Group Inc.370,194$47K0.0%-33.4%27.834% 5/16/2025 Goldman Sachs Group Inc.370,194$47K0.0%-33.4%0.559% 2/17/2025 Two Sigma Investments LP209,997$43K0.0%-25.7%0.321% 2/17/2025 Two Sigma Advisers LP385,500$80K0.0%-16.3%0.589% 2/17/2025 BNP Paribas Financial Markets244,920$51K0.0%N/A0.374% 2/14/2025 Samsara BioCapital LLC1,965,689$406K0.1%-29.3%3.003% 2/14/2025 Northern Trust Corp286,310$59K0.0%+56.2%0.437% Get the Latest News and Ratings for LYRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/13/2025 ADAR1 Capital Management LLC533,200$110K0.0%N/A0.815% 2/12/2025 Geode Capital Management LLC885,966$183K0.0%+15.3%1.353% 2/12/2025 JPMorgan Chase & Co.156,442$32K0.0%+161.8%0.239% 11/15/2024 State Street Corp488,720$126K0.0%+88.1%0.747% 8/6/2024 Acadian Asset Management LLC985,631$271K0.0%N/A1.617% 7/12/2024 Rosalind Advisors Inc.1,034,773$286K0.2%-9.6%1.697% 5/17/2024 Ikarian Capital LLC1,056,829$6.57M0.7%-15.7%1.733% 5/10/2024 Vanguard Group Inc.1,481,481$9.22M0.0%+38.3%2.430% 4/25/2024 Rosalind Advisors Inc.1,144,524$7.12M6.7%-39.4%1.916% 2/15/2024 Parkman Healthcare Partners LLC754,885$3.96M0.6%+20.8%1.436% 2/14/2024 Vestal Point Capital LP3,000,000$15.72M1.7%N/A5.708% 2/13/2024 Armistice Capital LLC1,088,000$5.70M0.1%-29.8%2.070% 2/7/2024 Jump Financial LLC16,737$88K0.0%N/A0.032% 1/25/2024 Heritage Wealth Management Inc. Texas10,000$52K0.0%N/A0.019% 12/6/2023 Citigroup Inc.67,677$265K0.0%N/A0.129% 11/15/2023 Armistice Capital LLC1,550,000$6.06M0.1%-61.4%2.949% 11/14/2023 Prescott Group Capital Management L.L.C.30,000$117K0.0%N/A0.057% 10/24/2023 Bank of New York Mellon Corp18,621$73K0.0%N/A0.038% 8/24/2023 Perceptive Advisors LLC12,757,562$52.43M1.5%+39.5%25.747% 8/14/2023 Samsara BioCapital LLC2,780,261$11.43M2.0%+56.4%8.733% 8/14/2023 Pura Vida Investments LLC1,413,242$5.72M0.8%-29.2%4.439% 8/10/2023 Letko Brosseau & Associates Inc.31,900$131K0.0%N/A0.100% 2/15/2023 Nantahala Capital Management LLC2,220,830$6.97M0.5%-1.1%6.977% 2/14/2023 Pura Vida Investments LLC2,157,298$6.77M0.3%-14.1%6.778% 11/15/2022 Pura Vida Investments LLC2,510,302$12.58M0.7%-2.6%7.888% 11/14/2022 Boothbay Fund Management LLC34,721$174K0.0%-9.5%0.109% 11/10/2022 Nantahala Capital Management LLC2,245,830$11.25M0.7%-5.2%17.262% 8/16/2022 Pura Vida Investments LLC2,576,196$14.56M0.8%+394.9%19.802% 8/16/2022CVI Holdings LLC60,822$344K0.0%N/A0.468% 8/15/2022 Nantahala Capital Management LLC2,369,668$13.39M0.7%N/A18.214% Google did what!?!? (Ad)A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.Gates and Altman are betting big—see why8/12/2022 Ensign Peak Advisors Inc56,229$318K0.0%+43.6%0.432% 8/12/2022 Ikarian Capital LLC347,338$1.96M0.4%-17.8%2.670% 5/16/2022 Clearline Capital LP119,924$482K0.1%+84.9%0.922% 2/14/2022 Clearline Capital LP64,862$283K0.0%N/A0.499% 2/14/2022 Soleus Capital Management L.P.10,000$44K0.0%-95.4%0.077% 2/11/2022 Pentwater Capital Management LP71,313$311K0.0%+122.8%0.548% 11/16/2021 Two Sigma Advisers LP58,000$529K0.0%+31.8%0.446% 11/15/2021 Pura Vida Investments LLC533,417$4.87M0.1%-1.7%4.103% 11/15/2021 Marshall Wace LLP12,457$114K0.0%-35.5%0.096% 11/9/2021BlackRock Inc.17,818$163K0.0%-11.4%0.137% 11/4/2021 Close Asset Management Ltd7,000$64K0.0%N/A0.054% 8/25/2021 Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/18/2021 Ikarian Capital LLC624,684$5.02M0.4%-20.0%4.805% 8/17/2021 Walleye Capital LLC19,093$153K0.0%N/A0.147% 8/17/2021 Millennium Management LLC155,135$1.25M0.0%N/A1.193% 8/17/2021 Bridgeway Capital Management LLC41,900$336K0.0%-14.5%0.322% 8/16/2021Tibra Equities Europe Ltd40,000$321K0.1%N/A0.308% 8/16/2021 Marshall Wace LLP19,321$155K0.0%-58.8%0.149% 8/13/2021 Geode Capital Management LLC36,102$289K0.0%-60.0%0.278% 8/13/2021 Vanguard Group Inc.220,029$1.77M0.0%+3.8%1.692% 8/12/2021 Trexquant Investment LP11,610$93K0.0%N/A0.089% 8/12/2021Ergoteles LLC31,000$249K0.0%N/A0.238% 8/11/2021 Deutsche Bank AG76,441$614K0.0%-5.4%0.588% 8/11/2021 Susquehanna International Group LLP21,529$173K0.0%N/A0.166% 8/2/2021 Advisor Group Holdings Inc.4,434$36K0.0%-89.6%0.034% 5/18/2021 Morgan Stanley107,217$1.24M0.0%+655.0%0.825% (Data available from 1/1/2016 forward) LYRA Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of LYRA shares? During the previous two years, 24 institutional investors and hedge funds held shares of Lyra Therapeutics. The most heavily invested institutionals were Vestal Point Capital LP ($15.72M), Vanguard Group Inc. ($9.22M), Ikarian Capital LLC ($6.57M), Armistice Capital LLC ($5.70M), Parkman Healthcare Partners LLC ($3.96M), Perceptive Advisors LLC ($2.29M), and Samsara BioCapital LLC ($406K).Learn more on Lyra Therapeutics' institutional investors. What percentage of Lyra Therapeutics' stock is owned by institutional investors? 95.62% of Lyra Therapeutics' stock is owned by institutional investors. Learn more on LYRA's institutional investor holdings. Which institutional investors have been buying Lyra Therapeutics' stock? Of the 16 institutional investors that purchased Lyra Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Vestal Point Capital LP ($3M), Acadian Asset Management LLC ($985.63K), ADAR1 Capital Management LLC ($533.20K), Vanguard Group Inc. ($410.02K), BNP Paribas Financial Markets ($244.92K), State Street Corp ($228.90K), and Parkman Healthcare Partners LLC ($129.83K). How much institutional buying is happening at Lyra Therapeutics? Institutional investors have bought a total of 1,331,495 shares in the last 24 months. This purchase volume represents approximately $14.31M in transactions. Which of Lyra Therapeutics' major shareholders have been selling company stock? The following institutional investors have sold Lyra Therapeutics stock in the last 24 months: Perceptive Advisors LLC ($12.50M), Geode Capital Management LLC ($1.01M), Samsara BioCapital LLC ($814.57K), Goldman Sachs Group Inc. ($370.63K), Two Sigma Advisers LP ($74.80K), and Two Sigma Investments LP ($72.55K). How much institutional selling is happening at Lyra Therapeutics? Institutional investors have sold a total of 14,839,980 shares in the last 24 months. This volume of shares sold represents approximately $133.29M in transactions. Related Companies PSTV Institutional Ownership MLSS Institutional Ownership NEPH Institutional Ownership WOK Institutional Ownership ECOR Institutional Ownership RBOT Institutional Ownership MODD Institutional Ownership NMTC Institutional Ownership POCI Institutional Ownership CLGN Institutional Ownership This page (NASDAQ:LYRA) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
